Literature DB >> 9038951

Intrapericardial administration of adenovirus for gene transfer.

K G Lamping1, C D Rios, J A Chun, H Ooboshi, B L Davidson, D D Heistad.   

Abstract

Gene transfer to the heart has been accomplished with intravascular administration of adenoviral vectors into the pericardial sac, by increasing the duration of exposure to the adenovirus, would result in gene expression in the pericardium and perhaps myocardium and therefore might provide an alternative method to intravascular administration for gene transfer. We injected a replication-deficient adenovirus (average 1 x 10(12) particles/ml in 3% sucrose; 1 x 10(10) plaque forming units/ml containing cDNA encoding a nuclear-targeted bacterial beta-galactosidase into the pericardial sac of dogs. Samples of the pericardium and heart were examined for enzymatic activity of beta-galactosidase and after histochemical staining with 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside. One day after injection of the adenovirus (1-3 ml), beta-galactosidase activity was highest in the parietal pericardium and left atrial tissue and lower in the right and left ventricles. Histochemical expression of the transgene was predominantly in the visceral pericardium of atria and ventricles and occasionally in the epicardial myocytes, arterioles, and venules. Pretreatment with doxycycline (5 mg) before adenovirus administration increased transgene activity in left ventricles. Thus adenovirus injected into the pericardial sac provides an effective method for gene transfer to the visceral and parietal pericardium over atria and ventricles.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9038951     DOI: 10.1152/ajpheart.1997.272.1.H310

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  14 in total

Review 1.  Clinical applications of vascular gene therapy.

Authors:  J Rutanen; T T Rissanen; A Kivelä; I Vajanto; S Ylä-Herttuala
Journal:  Curr Cardiol Rep       Date:  2001-01       Impact factor: 2.931

2.  Targeted Coronary Thrombolysis via "Pericardial" Administration of Lytic Agents?

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-09       Impact factor: 2.300

3.  Delivery of gelfoam-enabled cells and vectors into the pericardial space using a percutaneous approach in a porcine model.

Authors:  D Ladage; I C Turnbull; K Ishikawa; Y Takewa; K Rapti; C Morel; I Karakikes; L Hadri; J Müller-Ehmsen; K D Costa; R J Hajjar; Y Kawase
Journal:  Gene Ther       Date:  2011-04-21       Impact factor: 5.250

Review 4.  Delivery of gene and cellular therapies for heart disease.

Authors:  Justin A Mariani; David M Kaye
Journal:  J Cardiovasc Transl Res       Date:  2010-05-11       Impact factor: 4.132

Review 5.  Cardiac gene therapy: optimization of gene delivery techniques in vivo.

Authors:  Michael G Katz; JaBaris D Swain; Jennifer D White; David Low; Hansell Stedman; Charles R Bridges
Journal:  Hum Gene Ther       Date:  2010-04       Impact factor: 5.695

Review 6.  Targeted gene therapy for the treatment of heart failure.

Authors:  Kleopatra Rapti; Antoine H Chaanine; Roger J Hajjar
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

7.  Potential of gene therapy as a treatment for heart failure.

Authors:  Roger J Hajjar
Journal:  J Clin Invest       Date:  2013-01-02       Impact factor: 14.808

Review 8.  Gene therapy for heart failure.

Authors:  Lisa Tilemann; Kiyotake Ishikawa; Thomas Weber; Roger J Hajjar
Journal:  Circ Res       Date:  2012-03-02       Impact factor: 17.367

9.  Percutaneous transendocardial delivery of self-complementary adeno-associated virus 6 achieves global cardiac gene transfer in canines.

Authors:  Lawrence T Bish; Meg M Sleeper; Benjamin Brainard; Stephen Cole; Nicholas Russell; Elanor Withnall; Jason Arndt; Caryn Reynolds; Ellen Davison; Julio Sanmiguel; Di Wu; Guangping Gao; James M Wilson; H L Sweeney
Journal:  Mol Ther       Date:  2008-09-23       Impact factor: 11.454

10.  Targeted high-efficiency, homogeneous myocardial gene transfer.

Authors:  Tetsuo Sasano; Kan Kikuchi; Amy D McDonald; Shenghan Lai; J Kevin Donahue
Journal:  J Mol Cell Cardiol       Date:  2007-02-14       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.